[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644736":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":40,"collaborators":42,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":69,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prevention Group","EXPERIMENTAL","Prophylactic CD45RA-depleted DLI",[13],"Biological: CD45RA-depleted DLI",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","CD45RA-depleted DLI","CD45RA Depleted DLI by ex vivo CliniMACS® prepared from mononuclear cell leukapheresis",[9],null,[22],{"facility":5,"status":20,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Shanghai","SH","200025","China","CN",{"type":29,"coordinates":30},"Point",[31,32],121.45806,31.22222,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":20,"email":39},"Xiaoxia Hu, MD, PhD","CONTACT","008613795437259","hu_xiaoxia@126.com",{"type":41,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[43],{"name":44,"class":6},"Shanghai Liquan Hospital","100644736","phase-1-cd45ra-depleted-dli-for-the-prevention-of-viral-infections-in-high-risk-patients-after-haploidentical-transplantation-100644736",false,"NCT07672964","CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation","CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study","CD45RADLIPx","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Patients undergoing allogeneic hematopoietic stem cell transplantation (any conditioning regimen or graft source is allowed).\n* Presence of at least one high-risk factor for post-transplant viral infection (any of the following):\n* Age ≥50 years or ≤14 years\n* Non-sibling matched transplantation\n* In vivo or ex vivo T-cell depletion\n* Myeloablative conditioning\n* Conditioning containing radiotherapy\n* Second transplantation\n* CMV IgG or EBV IgG donor\u002Frecipient mismatch (donor positive, recipient negative)\n* History of grade II or higher acute graft-versus-host disease (aGVHD) after transplantation and use of high-dose corticosteroids (prednisone equivalent ≥1 mg\u002Fkg\u002Fday)\n* Availability of a suitable lymphocyte donor (see \"Donor Selection Criteria\").\n* Adequate organ function meeting the following laboratory criteria:\n* Liver function: ALT and AST ≤10× upper limit of normal (ULN); total bilirubin ≤5× ULN\n* Renal function: BUN and creatinine ≤1.25× ULN\n* No cardiac dysfunction on electrocardiogram or echocardiogram\n* Pulmonary function: oxygen saturation \\>90% without supplemental oxygen\n* The patient or legal guardian has the desire and request to receive treatment, signs the informed consent form before treatment, and is willing to comply with the treatment plan, follow-up schedule, and laboratory tests.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from this study:\n\n* Active grade II-IV acute graft-versus-host disease (aGVHD)\n* Active aGVHD requiring prednisone or equivalent corticosteroid \\>0.5 mg\u002Fkg\u002Fday\n* Active viral infection\n* Uncontrolled or relapsed malignancy\n* Other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or affect informed consent, study participation, follow-up, or interpretation of results.","ALL","14 Years","50 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61],"PHASE1","The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\nDoes this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?",[64,65],"Hematologic Malignancy","Haplo-identical HCT",[67,68],"CD45RA","DLI","NOT_YET_RECRUITING","2026-06-22",{"date":72,"type":73},"2026-06-29","ACTUAL",{"date":75,"type":58},"2026-07-01",{"date":77,"type":58},"2028-07-31",{"name":5,"class":6},1]